Intellia’s (NTLA) CRISPR Therapies Show Promise Amid Competition

While Intellia’s (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

Leave a comment

Your email address will not be published. Required fields are marked *